News & EventsSTERNA BIOLOGICALS
Keep up to date with sterna biologicals – read our latest news and find out where you can meet us
Company news
-
sterna biologicals announces strategic corporate update
Marburg, Germany, July 17, 2024
sterna biologicals GmbH (sterna), a clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, today announced a strategic update to the development and commercialization of its lead therapeutic candidate, hgd40.
-
sterna biologicals announces dosing of first patient in phase IIA proof-of-concept study with SB010 in moderate to severe asthma
Marburg, Germany, December 14, 2021
- GIANT-1 study to evaluate once-daily oral inhalation of novel catalytic antisense oligonucleotide formulation SB010 in patients with moderate to severe Type-2 driven asthma
- Standard of care remains insufficient for large number of these asthmatics
- Study incorporates digital therapy to enhance patient device handling, increase adherence, reduce drop-out rates and generate maximally reliable data through reduction of inter-patient variability
-
sterna biologicals receives approval for innovative phase II a study design in asthma combining a novel antisense-based treatment with a digital therapy
Marburg, Germany, November 23, 2021
- Phase IIa proof-of-concept (POC) study with novel catalytic antisense oligonucleotide SB010 in patients with moderate to severe asthma initiated.
- Innovative study design combines pharmacological therapy with VisionHealth’s Kata® Clinical, a unique combination of artificial intelligence, and computer animation to enhance patients’ device handling, adherence, reduce drop-out rates and generate maximally reliable data due to reduced inter-patient variability
Upcoming events
Will be updated soon ...